Cancer Research UK (CRUK) and biotech company Aleta Biotherapeutics have entered into a collaboration on the early phase clinical development of Aleta’s blood cancer therapy candidate ALETA-001. ALETA-001 is a CAR-T cell engager candidate, which has been developed for the potential treatment of people with B-cell lymphoma and leukaemia whose disease has progressed following CD19 CAR-T cell therapy. Source: Pharmatimes 23/6/21